Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Arginine-Glycine-Aspartic Acid-anchored Curcumin-based Nanotherapeutics Inhibit Pyroptosis-induced Cytokine Release Syndrome for In Vivo and In Vitro Sepsis Applications

Author(s): Yi Shi, Qian Wu, Yi Lu, Ling-Peng Meng, Xiao-Ling Xu*, Xiao-Juan Wang and Wei Chen*

Volume 29, Issue 4, 2023

Published on: 08 February, 2023

Page: [283 - 294] Pages: 12

DOI: 10.2174/1381612829666230201144029

Price: $65

Abstract

Aim: We aimed to design RGD-anchored liposomes encapsulating an antipyroptosis drug that could efficiently target macrophages and relieve the rate of cytokine release syndrome, providing a new strategy for sepsis treatment, especially sepsis-induced acute renal injury.

Background: Sepsis is a clinical syndrome of life-threatening organ dysfunction caused by host response disorders due to infection. Sepsis has a high incidence and remains one of the leading causes of death worldwide.

Objective: Macrophage-mediated pyroptosis plays an important role in the occurrence and development of cytokine release syndrome and organ injury caused by sepsis. Curcumin can inhibit inflammasome assembly and slow the progression of pyroptosis by scavenging intracellular reactive oxygen species, but it has poor water solubility and low bioavailability. The emergence of drug-delivery nanosystems has overcome this problem, but there is still a lack of research on how to accurately deliver antipyroptotic drugs to innate immune cells and subsequently hinder pyroptosis.

Methods: We constructed a curcumin-loaded RGD-modified liposome (RGD-lipo/Cur) and demonstrated that RGD-lipo/Cur could effectively target macrophages.

Results: In vitro, RGD-lipo/Cur reduced the upregulation of caspase-1, caspase-3, NLRP3, IL-1β and GSDMD, inhibiting pyroptosis, reducing oxidative stress, and attenuating the proinflammatory cytokine cascade. Conclusion: RGD-lipo/Cur was considered to have great potential for sepsis treatment.

« Previous Next »
[1]
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315(8): 801-10.
[http://dx.doi.org/10.1001/jama.2016.0287] [PMID: 26903338]
[2]
Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. Lancet 2018; 392(10141): 75-87.
[http://dx.doi.org/10.1016/S0140-6736(18)30696-2] [PMID: 29937192]
[3]
Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: Analysis for the global burden of disease study. Lancet 2020; 395(10219): 200-11.
[http://dx.doi.org/10.1016/S0140-6736(19)32989-7] [PMID: 31954465]
[4]
Lu F, Hong Y, Liu L, et al. Long noncoding RNAs: A potential target in sepsis-induced cellular disorder. Exp Cell Res 2021; 406(2): 112756.
[http://dx.doi.org/10.1016/j.yexcr.2021.112756] [PMID: 34384779]
[5]
Aki T, Unuma K, Uemura K. The role of peroxiredoxins in the regulation of sepsis. Antioxidants 2022; 11(1): 126.
[http://dx.doi.org/10.3390/antiox11010126] [PMID: 35052630]
[6]
Robinson N, Ganesan R, Hegedűs C, Kovács K, Kufer TA, Virág L. Programmed necrotic cell death of macrophages: Focus on pyroptosis, necroptosis, and parthanatos. Redox Biol 2019; 26: 101239.
[http://dx.doi.org/10.1016/j.redox.2019.101239] [PMID: 31212216]
[7]
Kumar A, Harsha C, Parama D, et al. Current clinical developments in curcumin-based therapeutics for cancer and chronic diseases. Phytother Res 2021; 35(12): 6768-801.
[http://dx.doi.org/10.1002/ptr.7264] [PMID: 34498308]
[8]
Fuloria S, Mehta J, Chandel A, et al. A comprehensive review on the therapeutic potential of Curcuma longa linn. in relation to its major active constituent curcumin. Front Pharmacol 2022; 13: 820806.
[http://dx.doi.org/10.3389/fphar.2022.820806] [PMID: 35401176]
[9]
Burge K, Gunasekaran A, Eckert J, Chaaban H. Curcumin and intestinal inflammatory diseases: Molecular mechanisms of protection. Int J Mol Sci 2019; 20(8): 1912.
[http://dx.doi.org/10.3390/ijms20081912] [PMID: 31003422]
[10]
Praditya D, Kirchhoff L, Brüning J, Rachmawati H, Steinmann J, Steinmann E. Anti-infective properties of the golden spice curcumin. Front Microbiol 2019; 10: 912.
[http://dx.doi.org/10.3389/fmicb.2019.00912] [PMID: 31130924]
[11]
Sohn SI, Priya A, Balasubramaniam B, et al. Biomedical applications and bioavailability of curcumin-an updated overview. Pharmaceutics 2021; 13(12): 2102.
[http://dx.doi.org/10.3390/pharmaceutics13122102] [PMID: 34959384]
[12]
Khalil NM, Nascimento TCF, Casa DM, et al. Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf B Biointerfaces 2013; 101: 353-60.
[http://dx.doi.org/10.1016/j.colsurfb.2012.06.024] [PMID: 23010041]
[13]
Geo HN, Murugan DD, Chik Z, et al. Renal nano-drug delivery for acute kidney injury: Current status and future perspectives. J Control Release 2022; 343: 237-54.
[http://dx.doi.org/10.1016/j.jconrel.2022.01.033] [PMID: 35085695]
[14]
Colombo M, Bianchi A. Click chemistry for the synthesis of RGD-containing integrin ligands. Molecules 2010; 15(1): 178-97.
[http://dx.doi.org/10.3390/molecules15010178] [PMID: 20110882]
[15]
Yang M, Zhang ZC, Liu Y, et al. Function and mechanism of RGD in bone and cartilage tissue engineering. Front Bioeng Biotechnol 2021; 9: 773636.
[http://dx.doi.org/10.3389/fbioe.2021.773636] [PMID: 34976971]
[16]
Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci 2008; 103(1): 4-13.
[http://dx.doi.org/10.1093/toxsci/kfm246] [PMID: 17890765]
[17]
Van Hove I, Hu TT, Beets K, et al. Targeting RGD-binding integrins as an integrative therapy for diabetic retinopathy and neovascular age-related macular degeneration. Prog Retin Eye Res 2021; 85: 100966.
[http://dx.doi.org/10.1016/j.preteyeres.2021.100966] [PMID: 33775825]
[18]
Salehi Najafabadi P, Delaviz H, Asfaram A, et al. Evaluation of the biodistribution of arginine, glycine, aspartic acid peptide-modified nanoliposomes containing curcumin in rats. Iran J Biotechnol 2022; 20(2): e2990.
[PMID: 36337060]
[19]
Jiang K, Shen M, Xu W. Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: In vitro/vivo evaluation. Int J Nanomedicine 2018; 13: 2561-9.
[http://dx.doi.org/10.2147/IJN.S157746] [PMID: 29731631]
[20]
Garanti T, Alhnan MA, Wan KW. RGD-decorated solid lipid nanoparticles enhance tumor targeting, penetration and anticancer effect of asiatic acid. Nanomedicine 2020; 15(16): 1567-83.
[http://dx.doi.org/10.2217/nnm-2020-0035] [PMID: 32618517]
[21]
He W, Wan H, Hu L, et al. Gasdermin D is an executor of pyroptosis and required for interleukin-1β secretion. Cell Res 2015; 25(12): 1285-98.
[http://dx.doi.org/10.1038/cr.2015.139] [PMID: 26611636]
[22]
Makowski M, Silva ÍC, Pais do Amaral C, Gonçalves S, Santos NC. Advances in lipid and metal nanoparticles for antimicrobial peptide delivery. Pharmaceutics 2019; 11(11): 588.
[http://dx.doi.org/10.3390/pharmaceutics11110588] [PMID: 31717337]
[23]
Yadav VR, Rao G, Houson H, et al. Nanovesicular liposome-encapsulated hemoglobin (LEH) prevents multi-organ injuries in a rat model of hemorrhagic shock. Eur J Pharm Sci 2016; 93: 97-106.
[http://dx.doi.org/10.1016/j.ejps.2016.08.010] [PMID: 27503458]
[24]
Zhang X, Bohner A, Bhuvanagiri S, et al. Targeted intraceptor nanoparticle for neovascular macular degeneration: Preclinical dose optimization and toxicology assessment. Mol Ther 2017; 25(7): 1606-15.
[http://dx.doi.org/10.1016/j.ymthe.2017.01.014] [PMID: 28236576]
[25]
Tian T, Cao L, He C, et al. Targeted delivery of neural progenitor cell-derived extracellular vesicles for anti-inflammation after cerebral ischemia. Theranostics 2021; 11(13): 6507-21.
[http://dx.doi.org/10.7150/thno.56367] [PMID: 33995671]
[26]
Kwon SP, Hwang BH, Park EH, et al. Nanoparticle-mediated blocking of excessive inflammation for prevention of heart failure following myocardial infarction. Small 2021; 17(32): 2101207.
[http://dx.doi.org/10.1002/smll.202101207] [PMID: 34216428]
[27]
Zhou L, Ye Z, Zhang E, et al. Co-delivery of dexamethasone and captopril by α8 integrin antibodies modified liposome-plga nanoparticle hybrids for targeted anti-inflammatory/anti-fibrosis therapy of glomerulonephritis. Int J Nanomedicine 2022; 17: 1531-47.
[http://dx.doi.org/10.2147/IJN.S347164] [PMID: 35388271]
[28]
Mirzaaghasi A, Han Y, Ahn SH, Choi C, Park JH. Biodistribution and pharmacokinectics of liposomes and exosomes in a mouse model of sepsis. Pharmaceutics 2021; 13(3): 427.
[http://dx.doi.org/10.3390/pharmaceutics13030427] [PMID: 33809966]
[29]
Wang X, Li X, Liu S, et al. PCSK9 regulates pyroptosis via mtDNA damage in chronic myocardial ischemia. Basic Res Cardiol 2020; 115(6): 66.
[http://dx.doi.org/10.1007/s00395-020-00832-w] [PMID: 33180196]
[30]
Kang JY, Xu MM, Sun Y, et al. Melatonin attenuates LPS-induced pyroptosis in acute lung injury by inhibiting NLRP3-GSDMD pathway via activating Nrf2/HO-1 signaling axis. Int Immunopharmacol 2022; 109: 108782.
[http://dx.doi.org/10.1016/j.intimp.2022.108782] [PMID: 35468366]
[31]
Ding B, Sheng J, Zheng P, et al. Biodegradable upconversion nanoparticles induce pyroptosis for cancer immunotherapy. Nano Lett 2021; 21(19): 8281-9.
[http://dx.doi.org/10.1021/acs.nanolett.1c02790] [PMID: 34591494]
[32]
Evavold CL, Hafner-Bratkovič I, Devant P, et al. Control of gasdermin D oligomerization and pyroptosis by the Ragulator-Rag-mTORC1 pathway. Cell 2021; 184(17): 4495-4511.e19.
[http://dx.doi.org/10.1016/j.cell.2021.06.028] [PMID: 34289345]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy